Eagle Pharmaceuticals' GAAP net income for 3 months of 2022 was $44.058 million, compared to a loss of $0.421 million in the previous year. Revenue increased 2.8 times to $115.874 million from $41.249 million a year earlier.

Eagle Pharmaceuticals acquires pharmaceutical company Acacia Pharma for €94.7 million. Acacia develops drugs designed to help patients recover from surgery or chemotherapy. The deal is expected to close at the end of Q2 2022.

Eagle Pharmaceuticals' GAAP loss for 2021 was $8.627 million, compared to a profit of $11.989 million in the previous year. Revenues fell 8.7% to $171.546 million from $187.802 million a year earlier.

Eagle Pharmaceuticals' GAAP loss for 9M 2021 was $2.431 million, compared to a profit of $3.932 million in the previous year. Revenue declined 6.3% to $129.226 million from $137.886 million a year earlier.